We thank Richard Lieber and Shannon Bremner for their ImageJ macro and instructions. While at Thomas Jefferson University, this work was supported by the Pennsylvania Department of Health CURE Grant TJU No. 080-37038-AI0801. Subsequently, this study was supported by a grant to AB from the National Institutes of Health (R21CA190028), and by grants to TAZ from the National Institutes of Health (R01CA122596, R01CA194593), the IU Simon Cancer Center, the Lustgarten Foundation, the Lilly Foundation, Inc., and the IUPUI Pancreas Signature Center.

伦理学声明:描述了托马斯·杰斐逊大学的机构动物护理和使用委员会和医学的印第安纳大学医学院获得批准的所有研究。 1. C26细胞生长和准备<ol><li>获得C26结肠癌细胞（俄亥俄州立大学医学中心（OSUMC）），并准备完整生长培养基（ 即，高葡萄糖的Dulbecco改良的Eagle氏培养基（DMEM）中含有10％胎牛血清（FBS），1mM丙酮酸钠，1％谷氨酰胺和1％链霉素/青霉素）。 注意:为了允许更好-实验间再现性，优选的是使用C26细胞以尽可能低的通路。 </li><li>使用市售的细胞计数器直接制版50000个细胞/厘米2在完全生长培养基的烧瓶。孵育他们在湿润气氛中，在37℃和5％的CO 2，直至亚汇合。避免在高密度培养他们上一个耳鼻喉科分化和细胞表型的漂流。 </li><li>第一通道之后，板足够的细胞在动物的计划数量被植入。对细胞植入的当天，解离通过胰蛋白酶消化细胞以每平方厘米0.02毫升0.25％胰蛋白酶-EDTA溶液中，加入每毫升胰蛋白酶的新鲜培养基至少3毫升中和胰蛋白酶，确定在细胞/ ml的细胞浓度和重悬需要在无菌PBS的实验（每只小鼠1×10 6个细胞）细胞的数量。 注:C26细胞达到汇合时，密度为约500,000个细胞/厘米2。 </li></ol> 2.小​​鼠<ol><li>随机成年CD2F1小鼠（至少8周龄）​​分组（通常控制和肿瘤承载）与至少n =每组6。 注:C26肿瘤的Balb / c小鼠生长为好。然而，根据我们的经验，CD2F1小鼠代表对于该特定肿瘤模型更通用的和经济的主机。此外，类似于临床设置，并在与癌症相关的肌肉的其它实验模型报告发现浪费14-16，在响应于C26恶病质的性别差异也可以观察到17（也见表1）。 </li><li>使用麻醉异氟烷吸入（氧气3％）鼠标。维持麻醉下的动物只要执行的肿瘤接种所需的时间。确保鼠标为了防止体热的损失位于一个加热垫。启动肿瘤注射过程之前，轻轻捏脚趾后方适当的确认麻醉。 注意:由于该过程（通常在几秒钟）的持续时间，不需要使用兽医眼膏。出于同样的原因，经受假手术对照动物预计不会减肥。 </li><li>使用无菌1毫升注射器，胰岛素用26号针头，迅速注入250微升含有T中的解决方案umor细胞在小鼠的脂肪垫皮下和intrascapularly。 注:控制动物将接受250微升无菌生理盐水intrascapularly的脂肪垫。 </li><li>将它在笼中动物回来。直接观察到鼠标至少每隔15分钟，直到它可以轻柔的操作作出反应，并收复了一个翻正反射。 注意:不要离开鼠标无人值守，并保持在一个包含固体基质温恢复笼子。另外，不要的鼠标返回到动物室，直到它完全从麻醉中恢复。通常，小鼠不需要进行单独圈养，除非研究者旨在评估个体的食物摄取。如果是这种情况，并使用自动代谢笼不可用，食品消费的人工记录，必须有可能每天，每天在同一时间执行。 </li><li>每天检查小鼠并记录他们的体重。 注:录制体况评分和家笼行为可以分化程度的恶病质和病态行为，这是治疗研究18有益的。 </li></ol> 3.安乐死和采血车<ol><li>当在肿瘤中宿主体重损失比对照达到5％，10％，或15％（轻度，中度，重度恶病质，分别地）相比，其初始体重，安乐死的小鼠。 注:在一组达到体重减轻10％，在其所有的时间组处死一个典型的实验将进行。体重损失是通过测量体重包容了肿瘤的评估。 </li><li>将鼠标异氟醚全身麻醉（氧气3％）下。 （ - 1.5毫升约1）通过心脏穿刺的方法抽血。 </li><li>收集血K 2 -EDTA（18毫克），空管，将它们放在冰上。离心血液（2,000 XG在4℃15分钟），并收集血浆/血。 </li><li>用C的方式安乐死鼠标ervical错位。继续组织切除和器官集合。 </li></ol> 4.组织和器官切除注:对于使用生物化学和分子生物学实验的组织，计划权衡每个器官和组织，并立即将一个片段插入预先标记的冷冻管。快冷冻在液氮中，并储存于-80℃。 <ol><li>为了避免与毛皮组织样品的污染，喷在整个主体70％的乙醇。 </li><li>放置在解剖床鼠标在仰卧位置和由脚连接到升高的滴定管夹垂直延伸肢体。 </li><li>抓住与杜蒙钳下肢的皮肤，并使用弧形细剪刀轻轻除去皮肤和筋膜，暴露下肢下面的肌肉肚子。 </li><li>在上后股骨的外侧和内侧髁和其在插入标识腓肠肌上后下肢由其原点通过跟腱跟骨。 <ol><li>继续削减腓肠肌跟腱。抓住与杜蒙钳腓肠肌的远端拉肌腹朝它的起源。使用剪刀，切割肌肉在原点尽可能接近到股骨。将肌肉中的一道菜。立即称重并在液氮冷冻管它。 注:请不要与腓肠肌切除以及比目鱼肌。如果发生这种情况，仔细地用钳子轻轻拉动它关闭删除比目鱼。 </li></ol></li><li>继续识别和胫骨和其在通过其远端肌腱的内侧楔插入前外侧表面切除从它的起源胫骨前肌。 <ol><li>为了具有杠杆作用，通过抓住与食指和拇指数字握住脚。将杜蒙钳尖端立即胫浅表肌腱远端下，移动镊子使得BLUNT侧可用于从底层结缔组织分离胫肌腹。 </li><li>切使用细弯曲剪刀远端肌腱，然后切开肌肉在原点，尽可能靠近胫骨。 </li></ol></li><li>通过进行矢状切口在下腹区域开始和优移动到胃脘区域，停止只是隔膜上方的切口打开腹腔。 注:切口的深度应当只足以破坏腹肌壁和底层腹膜筋膜。 </li><li>小心地用钝尖镊子抓它取下肝脏，并用细弯剪刀解剖走任何血管或结缔组织附着在肝脏的腔。小心不要留下任何瓣后面。称重和捕捉冷冻肝在液氮中的管。 </li><li>使用钝头镊子，搬开肠，然后揭露和微妙删除脾脏。用钝尖镊子轻轻抓住健脾和使用细弯剪刀的背面或侧面钝解剖走任何结缔组织或血管秉承脾腔。称重和管理单元冻结它在液态氮的管。 </li><li>识别性腺脂肪垫，相邻的附睾（男性）或子宫（女性）。轻轻抓住用钝尖镊子附睾脂肪垫和拉组织了腔。使用细弯剪，切去可以连接到脂肪垫任何性腺组织。称取脂肪垫和捕捉冻结它在液氮管。 注意:通常，这种脂肪组织被认为是代表在小鼠中的总身体脂肪量的和中重量与恶病质下降。其他脂肪垫可以类似地确定，解剖，取出，称重。 </li><li>使用弧形细剪刀剪开动物的胸部。切除附着在ST的两个侧边框肋骨ernum。取出胸骨。使用两对镊子，把握胸廓的每一侧和横向拉每一侧以打开胸腔。 </li><li>娇柔与镊子拔出心脏。通过在左心房切断主动脉切除小心地用细弯剪刀心脏。确保通过微妙的印迹是对一些吸水纸空的任何残血的器官。称重和管理单元冻结它在液态氮的管。 </li></ol> 5.肌肉冻结和安装<ol><li>浸入含异戊烷入液氮的小塑料烧杯（50ml）中的下半部分。异戊烷是准备使用时稍微变粘稠并形成固体白色叠层衬烧杯内（温度:-160℃）。 注:请始终使用无火花青铜或铝制手动工具。避免吸入蒸气产品。保持通风良好。如果处理的泄漏和通风是不可能或impractic人，穿合适的呼吸器。 </li><li>由（10秒）短暂地将其浸入异戊烷冻结卡盘（软木）一些包埋剂。 </li><li>由肌腱，垂直相对于软木保持它，以维持纤维的取向，并允许截面处理肌肉（例如 ，胫骨或腓肠肌）。 </li><li>仔细定位在冷冻包埋介质顶部的新鲜肌肉的端部。 注:肌肉会坚持。不完全包围与包埋介质肌肉是很重要的。同样重要的是要保持的截面积的连续测定的垂直方向。 </li><li>蘸用所附肌肉入异戊烷浴夹头（通常冷冻时间为7 - 15秒，这取决于样品的大小和组合物）。 注:浸没在冷冻溶液不应持续超过需要完全冻结标本。冻结时间过长会压裂TURE的组织块，而时间太短会造成冰晶形成。一个良好的冰冻标本会变得更白。 </li><li>冷冻样品后，将其放入一个小塑料袋或样品管（50毫升）中，并立即在-80℃或在液氮中保存在冰柜。 </li></ol> 6.原始数据的分析<ol><li>为了控制在小鼠的大小变化，正常化的最终体重（FBW）;无瘤体重;和胎体，器官，并根据该初始体重（IBW）组织重量（以克表示），以及表达它们为"重量/ 100毫克IBW"。 注意:可替换地，一些研究者正常化肌肉量对于胫骨的长度。 </li><li>使用数据分析软件。找到的归一化权重的平均值和SD。执行与控制和承载C26小鼠之间不成对学生t检验进行统计分析。 注:结果可以相对于身体IBW呈现（和FBW）无肿瘤，肿瘤，器官和组织重量。 </li></ol> 7.肌肉切片<ol><li>低温恒温器内室的工作温度设置为围绕-23℃。 </li><li>允许标本（以前保存在-80°C）的工作温度（一两个小时应该足够）适应新环境。 </li><li>切的多个检体（优选胫前或腓肠肌），并收集它们在载玻片上的8微米厚的切片。 注:以肌肉的中腹区切段。 另外，为了准确起见，切段垂直于所述安装轴线。 </li><li>保持载玻片低温恒温器腔室内部。不要让如果目的是执行IF / IHC研究或酶染色它们解冻。 </li><li>在-80℃下用于进一步分析存储的幻灯片。 </li></ol> 8.评估肌纤维大小的层粘连蛋白免疫（方案1） 19。虽然肌肉切片的H＆E染色代表形态分析有价值的，方便的方法，使用一个IF方法14是显著更快，谦虚比基于E-H＆方法更准确。 H＆E方法描述如下。 <ol><li>无论从低温恒温器或-80℃储存空间中移除的组织切片，并允许他们平衡至室温（约5 - 10分钟）。 注意:为了避免与在小鼠中引发初级抗体相关的非特异性相互作用，最好是在另一个物种要么凸起使用抗体或利用市售的"小鼠 - 上 - 小鼠"免疫检测试剂盒的。 </li><li>浸入预冷的章节编甲醇（-20℃）10分钟。 </li><li>洗在室温下1×PBS中的部分5分钟。 </li><li>除去PBS中并用于免疫组织化学应用的笔以环绕在幻灯片的节。不要让部分在任何时候完全干燥。 </li><li>应用一个合适的封闭缓冲液（5 - 8％FBS的PBS或PBS中的5％山羊血清）到部分在RT 1小时。 </li><li>除去封闭缓冲液。 </li><li>在潮湿的腔室申请任一个的兔抗层粘连蛋白（1:30）或小鼠抗肌营养不良蛋白（1:30）的第一抗体在室温封闭缓冲液的章节2小时（或在4℃过夜）。 </li><li>洗用1×PBS切片5分钟。 </li><li>除去洗涤缓冲液，并在1×PBS中再次洗涤切片5分钟。 </li><li>除去洗涤缓冲液，并应用适当的荧光第二抗体（1:在封闭缓冲液1,000）在潮湿的腔室在RT 1小时至部分。 </li><li>去除二级抗体并用1×PBS洗涤切片5分钟。 </li><li>除去洗涤缓冲液并重复用1×PBS洗涤5分钟。除去洗涤缓冲液并覆盖使用的水基介质与玻璃盖的部分。 </li><li>通过使用染色的部分的数字图像识别肌肉的形态学特征。为了做到这一点，使用倒置荧光显微镜光IF部分（10倍或20倍放大倍率的目标是合适的），以及用数码相机和图像采集软件。将每个数字图像中的比例尺（20 - 30随机字段被推荐用于各肌肉部分），方便的CSA的量化。图像应保存在.TIF格式为与使用ImageJ的程序的图像分析软件兼容。 </li><li>使用ImageJ的宏通过荧光第二抗体在20肌内膜存在区分收缩组织（肌纤维大小）结缔组织。 注:宏和说明可从AUTHORS，理查德·利伯和Shannon布雷姆纳。 </li><li>通过双击桌面上的图标，打开ImageJ的程序。 </li><li>通过一次单击"插件"选项卡中加载CSA宏。向下移动光标通过单击一次选择"安装"选项。 </li><li>从已保存在文件夹中选择IT负载截宏，然后单击"打开"。 </li><li>一旦宏已被打开，点击"文件"，然后"打开"，从工具栏中的ImageJ打开包含比例尺的组织形象。 </li><li>一旦图像被打开，通过点击与直线的图标选择在ImageJ的程序中的"直线工具"。 </li><li>一旦"直线工具"时，上规模栏最左边的结束单击一次，然后在比例尺的最右边的结束单击一次。当正确完成，应该有覆盖在比例尺上的黄线。 </li><li>在确保黄釉W线性仍然覆盖规模栏上，单击一次选择从ImageJ的工具栏中的"分析"选项卡。 </li><li>在"分析"选项卡，将光标向下移动，并通过点击一次选择"设置规模"。 </li><li>在"设置规模"的窗口，不改变"以像素为单位距离"框中的值。在"已知距离"栏中输入的比例尺的已知距离。更改单位的"长度单位"框与比例尺单位（ 即微米=微米）相对应。最后，选择通过单击框"环球"一旦左边的"全球性"。 </li><li>关闭"设置规模"的窗口。 </li><li>打开第一图像通过按键盘上的"O"按钮来测量。观察一个窗口弹出窗口，允许用户查找并选择图像从已保存的文件夹进行测量。通过点击一次，然后点击选择图像"打开"。 </li> &lt;LI&gt;一旦打开，一个窗口应该出现在可接受范围CSA测量和圆的选择。 注意:这些设置通常被保留为默认值。但是，如果希望更改这些设置，一定要保持的值相同的每个连续图像中的实验来衡量。 </li><li>设置CSA范围和圆后，观察覆盖红色像素的图像与"门槛"窗口。调整图像的使用酒吧的门槛中的"阈值"窗口，直到肌肉纤维被准确地红色像素填充。 注:尝试以获得不会触碰彼此的纤维的最大数量;如果纤维是接触，它们会作为一个大的纤维，这将需要下游编辑来测量。 </li><li>设置阈值后，按键盘上的"1"按钮来衡量的肌肉纤维。 </li><li>圆圈黄线个别肌肉纤维。通过图像移动和移除伪像或已经由程序选择双纤维。要做到这一点，选择不点击他们一次纤维结构，然后按键盘上的"D"按钮。这将从测量删除它们。 </li><li>选择并从复制三围"测量值窗口"，并将其粘贴到进行进一步分析表格。 注意:得到的值也可以用于评估纤维分布分析，其通常表示一个有用的参数，以确定肿瘤生长是否促进向更小的肌纤维的转变。 </li><li>通过点击"X"，在窗口的左上角关闭所有在ImageJ的打开的窗口。 </li><li> 8.29 - 打开一个新的形象，按"O"，并重复步骤8.24来衡量。 </li></ol> 9.从H＆E染色切片肌纤维大小的评估（方案2） <ol><li>放置玻璃含有过滤哈里斯苏木8分钟滑入科普林罐子。 注:或者，如果可以不那么激烈的污渍需要使用迈耶苏木。 </li><li>冲洗在去离子水中的幻灯片。 </li><li>浸在自来水中的幻灯片长达5分钟。 </li><li>快速冲洗他们在去离子水中，然后孵育它们在过滤的1％伊红溶液为小于2分钟。 注意:如果一个更强烈的染色是期望的，加入1 - 乙酸2滴（0.01％或更少）的曙红溶液。 </li><li>开始脱水步骤。冲洗70％的乙醇的幻灯片不到1分钟。 </li><li>浸在90％乙醇的幻灯片1分钟。 </li><li>浸在95％乙醇的幻灯片1分钟。 </li><li>蘸100％乙醇的幻灯片2分钟。 </li><li>浸在二甲苯幻灯片2分钟。移动幻灯片含有新鲜二甲苯2分钟以上另外科普利罐子。 注意:保持在二甲苯的幻灯片（不超过1小时），直到它们被盖上盖玻片。 </li><li>放置coversliPS使用Permount或选择的基础二甲苯安装介质中的肌肉部分。 </li><li>观察H＆E染色载玻片用放大20倍的显微镜下，并获得整个肌肉部分区域的照片。通过使用一个明亮的光显微镜，数码相机和图像捕捉软件获取图像。 注意:在相同的放大倍数下拍摄一个微米的比例尺或图像的存在将要求确定的CSA。如上所述，至少20 - 30每块肌肉部分随机领域。 </li><li>评估使用ImageJ软件肌纤维的大小。打开所有的数字图像。设置如上述的比例。测量每使用手绘选择工具的肌肉至少1,500-2,000肌纤维，跟踪用鼠标纤维周围或更快的输入，与平板输入设备和一支笔。 </li></ol> 10.数据收集和分析<ol><li>为了建立肌肉纤维大小，评估的平均纤维"区域。"计算为每个肌肉，包括的面积和的Feret直径获得的测量装置和SD。另外，为了评价是否实验设置与朝任一较小或较大的肌纤维的移位相关联，分析了"纤维分布"。 </li><li>通过为两个组进行不成对t-检验评价结果的意义。确定用于C26小鼠组和对照组所获得的值之间的比率。上绘制报告手段SD和频率分布/柱状图旨在展示在纤维浸润转移的图表中的值。 </li></ol>

<ol>
	<li>Tan, B., Fearon, K. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Cachexia:+prevalence+and+impact+in+medicine.">Cachexia: prevalence and impact in medicine.</a> Curr Opin Clin Nutr Metab Care. 11, 400-407 (2008).</li><li>Aulino, P., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Molecular+cellular+and+physiological+characterization+of+the+cancer+cachexia-inducing+C26+colon+carcinoma+in+mouse.">Molecular cellular and physiological characterization of the cancer cachexia-inducing C26 colon carcinoma in mouse.</a> BMC cancer. 10, 363 (2010).</li><li>Bonetto, A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=STAT3+activation+in+skeletal+muscle+links+muscle+wasting+and+the+acute+phase+response+in+cancer+cachexia.">STAT3 activation in skeletal muscle links muscle wasting and the acute phase response in cancer cachexia.</a> PloS One. 6, e22538 (2011).</li><li>Bonetto, A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=JAK/STAT3+pathway+inhibition+blocks+skeletal+muscle+wasting+downstream+of+IL-6+and+in+experimental+cancer+cachexia.">JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia.</a> Am J Physiol Endocrinol Metab. 303, E410-E421 (2012).</li><li>Bonetto, A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Deacetylase+inhibitors+modulate+the+myostatin/follistatin+axis+without+improving+cachexia+in+tumor-bearing+mice.">Deacetylase inhibitors modulate the myostatin/follistatin axis without improving cachexia in tumor-bearing mice.</a> Current Cancer Drug Targets. 9, 608-616 (2009).</li><li>Acharyya, S., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Cancer+cachexia+is+regulated+by+selective+targeting+of+skeletal+muscle+gene+products.">Cancer cachexia is regulated by selective targeting of skeletal muscle gene products.</a> The Journal of Clinical Investigation. 114, 370-378 (2004).</li><li>Fearon, K., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Definition+and+classification+of+cancer+cachexia:+an+international+consensus.">Definition and classification of cancer cachexia: an international consensus.</a> The Lancet Oncology. 12, 489-495 (2011).</li><li>Holecek, M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Muscle+wasting+in+animal+models+of+severe+illness.">Muscle wasting in animal models of severe illness.</a> Int J Exp Pathol. 93, 157-171 (2012).</li><li>Acharyya, S., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Dystrophin+glycoprotein+complex+dysfunction:+a+regulatory+link+between+muscular+dystrophy+and+cancer+cachexia.">Dystrophin glycoprotein complex dysfunction: a regulatory link between muscular dystrophy and cancer cachexia.</a> Cancer Cell. 8, 421-432 (2005).</li><li>Benny Klimek, ., E, M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Acute+inhibition+of+myostatin-family+proteins+preserves+skeletal+muscle+in+mouse+models+of+cancer+cachexia.">Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia.</a> Biochemical and Biophysical Research Communications. 391, 1548-1554 (2010).</li><li>Pedroso, F. E., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Inflammation,+organomegaly,+and+muscle+wasting+despite+hyperphagia+in+a+mouse+model+of+burn+cachexia.">Inflammation, organomegaly, and muscle wasting despite hyperphagia in a mouse model of burn cachexia.</a> Journal of Cachexia, Sarcopenia and Muscle. 3, 199-211 (2012).</li><li>Soda, K., Kawakami, M., Kashii, A., Miyata, M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Manifestations+of+cancer+cachexia+induced+by+colon+26+adenocarcinoma+are+not+fully+ascribable+to+interleukin-6.">Manifestations of cancer cachexia induced by colon 26 adenocarcinoma are not fully ascribable to interleukin-6.</a> International journal of cancer. 62, 332-336 (1995).</li><li>Costelli, P., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=IGF-1+is+downregulated+in+experimental+cancer+cachexia.+American+journal+of+physiology.">IGF-1 is downregulated in experimental cancer cachexia. American journal of physiology.</a> Regulatory, Integrative and Comparative Physiology. 291, R674-R683 (2006).</li><li>Palus, S., Akashi, Y., von Haehling, S., Anker, S. D., Springer, J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=The+influence+of+age+and+sex+on+disease+development+in+a+novel+animal+model+of+cardiac+cachexia.">The influence of age and sex on disease development in a novel animal model of cardiac cachexia.</a> International Journal of Cardiology. 133, 388-393 (2009).</li><li>Norman, K., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Effect+of+sexual+dimorphism+on+muscle+strength+in+cachexia.">Effect of sexual dimorphism on muscle strength in cachexia.</a> Journal of Cachexia, Sarcopenia and Muscle. 3, 111-116 (2012).</li><li>Stephens, N. A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Sexual+dimorphism+modulates+the+impact+of+cancer+cachexia+on+lower+limb+muscle+mass+and+function.">Sexual dimorphism modulates the impact of cancer cachexia on lower limb muscle mass and function.</a> Clinical Nutrition. 31, 499-505 (2012).</li><li>Cosper, P. F., Leinwand, L. A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Cancer+causes+cardiac+atrophy+and+autophagy+in+a+sexually+dimorphic+manner.">Cancer causes cardiac atrophy and autophagy in a sexually dimorphic manner.</a> Cancer Research. 71, 1710-1720 (2011).</li><li>Ullman-Cullere, M. H., Foltz, C. J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Body+condition+scoring:+a+rapid+and+accurate+method+for+assessing+health+status+in+mice.">Body condition scoring: a rapid and accurate method for assessing health status in mice.</a> Laboratory Animal Science. 49, 319-323 (1999).</li><li>Bonetto, A., Andersson, D. C., Waning, D. L. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Assessment+of+muscle+mass+and+strength+in+mice.">Assessment of muscle mass and strength in mice.</a> Bonekey Rep. 4, 732 (2015).</li><li>Minamoto, V. B., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Increased+efficacy+and+decreased+systemic-effects+of+botulinum+toxin+A+injection+after+active+or+passive+muscle+manipulation.">Increased efficacy and decreased systemic-effects of botulinum toxin A injection after active or passive muscle manipulation.</a> Dev Med Child Neurol. 49, 907-914 (2007).</li><li>Murphy, K., Lynch, G. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Update+on+emerging+drugs+for+cancer+cachexia.">Update on emerging drugs for cancer cachexia.</a> Expert Opin Emerg Drugs. 14, 619-632 (2009).</li><li>Seto, D. N., Kandarian, S. C., Jackman, R. W. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=A+Key+Role+for+Leukemia+Inhibitory+Factor+in+C26+Cancer+Cachexia.">A Key Role for Leukemia Inhibitory Factor in C26 Cancer Cachexia.</a> The Journal of Biological Chemistry. 290, 19976-19986 (2015).</li><li>Judge, S. M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Genome-wide+identification+of+FoxO-dependent+gene+networks+in+skeletal+muscle+during+C26+cancer+cachexia.">Genome-wide identification of FoxO-dependent gene networks in skeletal muscle during C26 cancer cachexia.</a> BMC Cancer. 14, 997 (2014).</li><li>Kliewer, K. L., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Adipose+tissue+lipolysis+and+energy+metabolism+in+early+cancer+cachexia+in+mice.">Adipose tissue lipolysis and energy metabolism in early cancer cachexia in mice.</a> Cancer Biol Ther. 16, 886-897 (2015).</li><li>Aversa, Z., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Changes+in+myostatin+signaling+in+non-weight-losing+cancer+patients.">Changes in myostatin signaling in non-weight-losing cancer patients.</a> Ann Surg Oncol. 19, 1350-1356 (2012).</li><li>Bonetto, A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Early+changes+of+muscle+insulin-like+growth+factor-1+and+myostatin+gene+expression+in+gastric+cancer+patients.">Early changes of muscle insulin-like growth factor-1 and myostatin gene expression in gastric cancer patients.</a> Muscle Nerve. 48, 387-392 (2013).</li><li>Lazarus, D. D., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=A+new+model+of+cancer+cachexia:+contribution+of+the+ubiquitin-proteasome+pathway.">A new model of cancer cachexia: contribution of the ubiquitin-proteasome pathway.</a> The American Journal of Physiology. 277, E332-E341 (1999).</li><li>al-Majid, S., McCarthy, D. O. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Resistance+exercise+training+attenuates+wasting+of+the+extensor+digitorum+longus+muscle+in+mice+bearing+the+colon-26+adenocarcinoma.">Resistance exercise training attenuates wasting of the extensor digitorum longus muscle in mice bearing the colon-26 adenocarcinoma.</a> Biol Res Nurs. 2, 155-166 (2001).</li><li>Bonetto, A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=JAK/STAT3+pathway+inhibition+blocks+skeletal+muscle+wasting+downstream+of+IL-6+and+in+experimental+cancer+cachexia.">JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia.</a> American journal of physiology. Endocrinology and metabolism 303. 303, E410-E421 (2012).</li><li>Samuels, S. E., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Liver+protein+synthesis+stays+elevated+after+chemotherapy+in+tumour-bearing+mice.">Liver protein synthesis stays elevated after chemotherapy in tumour-bearing mice.</a> Cancer Lett. 239, 78-83 (2006).</li><li>Cornwell, E. W., Mirbod, A., Wu, C. L., Kandarian, S. C., Jackman, R. W. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=C26+cancer-induced+muscle+wasting+is+IKKbeta-dependent+and+NF-kappaB-independent.">C26 cancer-induced muscle wasting is IKKbeta-dependent and NF-kappaB-independent.</a> PloS One. 9, e87776 (2014).</li><li>Penna, F., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Muscle+wasting+and+impaired+myogenesis+in+tumor+bearing+mice+are+prevented+by+ERK+inhibition.">Muscle wasting and impaired myogenesis in tumor bearing mice are prevented by ERK inhibition.</a> PloS One. 5, e13604 (2010).</li></ol>

The authors have nothing to disclose.

特别是在其最新的阶段，大肠癌与恶病质的发展，这是负责不良预后和患者的生活质量降低有关。许多研究都集中在继发于癌症疾病的治疗;然而，尽管在这个方向上许多努力，但仍是癌症恶病质21没有批准的治疗。因此，当务之急是动物模型，以便最大限度地发现的翻译尽可能类似于人体病理学。 C26荷瘤小鼠是癌症恶病质22-24的一种常用的实验模型。这种模?...

肌肉消瘦是各种临床病症，如癌症，败血症，肝，肝硬化，心脏和肾功能衰竭，慢性阻塞性肺疾病，与爱滋病的严重并发症。特别是，肌肉消瘦在癌症患者1的至少50％是显而易见的。在从增加的蛋白质降解由于骨骼肌蛋白水解系统和/或从的过度活化癌症结果骨骼肌损失蛋白质合成6下降。脂解也是明显的，导致脂肪组织的消耗。在临床上，恶病质与减少质量和生活的长度相关联，并且估计为死亡的20的原因-癌症患者7的30％。实验模型，尽可能地类似于人类疾病的使用将是有益的。最佳动物模型的特点是高的再现性，以及由来自不同疗法有限干扰和不可预知的因素饮食，性别，遗传背景，通常是与临床病症8相关联。到目前为止，癌症恶病质已经主要研究了在动物模型特征在于癌细胞或致癌物注射的移植，虽然新的方法是使用转基因小鼠易患癌症的发展。 荷的C26癌（也被称为结肠-26和腺癌）代表癌症恶病质2,5的充分表征的和广泛使用的模型。的C26肿瘤导致的身体和肌肉重量损失的生长，主要是通过加强脂肪和蛋白质分解代谢9。一般地，10％的肿瘤重量与总体重与减少的骨骼肌重量20-25％和脂肪3,10更大消耗相关联。肝脾肿大也与肿瘤生长观察，与急性期反应的活化和促infla的高度沿mmatory细胞因子水平3,11。在这些中，它是众所周知的，IL-6起着在C26模型中介肌肉消瘦举足轻重的作用，即使该细胞因子可能不是恶病质12的唯一诱导剂。升高的IL-6引起肌肉萎缩通过JAK / STAT3通路的活化，并且抑制该转录因子能够防止肌肉萎缩3,4。 期间C26诱导肌肉消瘦，如肌肉萎缩的许多条件，肌肉质量在很大程度上是通过横跨肌纤维在肌肉蛋白质含量减少丢失，不通过细胞死亡或纤维13的损失。在C26恶病质，向更小的截面积的移位在两个糖酵解和氧化纤维2被观察到。这也具有降低的肌力5一致。全球许多团体，以便及时发现癌症CAC肌肉萎缩的新的调解员或临床相关的药品采取了C26型号的优势河虾。然而，对于使用这种模式的许多不同的程序已经报道，提高对所获得的数据的一致性的担忧，并在不同的实验条件下构成障碍重复性。这里，我们报告的产生标准化的和可重复的数据癌症恶病质的研究中通常会使用此模式。

<table border="0" cellpadding="0" cellspacing="0" width="661">
	<tbody>
		<tr height="21">
			<td height="21" style="height:21px;width:167px;">Cell culture Flasks</td>
			<td style="width:205px;">Falcon - Becton Dickinson</td>
			<td style="width:104px;">35-5001</td>
			<td style="width:185px;"></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:167px;">DMEM</td>
			<td style="width:205px;">Cellgro</td>
			<td style="width:104px;">10-017-CV</td>
			<td style="width:185px;"></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:167px;">FBS</td>
			<td style="width:205px;">Gibco</td>
			<td style="width:104px;">26140</td>
			<td style="width:185px;"></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:167px;">Streptomycin-Penicillin&#160;</td>
			<td style="width:205px;">Cellgro</td>
			<td style="width:104px;">30-002-CI</td>
			<td style="width:185px;"></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:167px;">CD2F1 mice</td>
			<td>Harlan</td>
			<td>060</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:167px;">Anesthesia apparatus</td>
			<td style="width:205px;">EZ-Anesthesia</td>
			<td style="width:104px;">EZ-7000</td>
			<td style="width:185px;"></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:167px;">2-Methyl Butane</td>
			<td style="width:205px;">Sigma-Aldrich</td>
			<td style="width:104px;">M32631</td>
			<td style="width:185px;"></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:167px;">OCT</td>
			<td style="width:205px;">Tissue-Tek</td>
			<td style="width:104px;">4583</td>
			<td style="width:185px;"></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:167px;">Cryostat</td>
			<td style="width:205px;">Leica</td>
			<td style="width:104px;">CM1850</td>
			<td style="width:185px;"></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:167px;">Cork disks</td>
			<td>Electron Microscopy Sciences</td>
			<td>63305</td>
			<td></td>
		</tr>
		<tr height="42">
			<td height="42" style="height:42px;width:167px;">Superfrost plus glass slides</td>
			<td>VWR</td>
			<td>48311-703</td>
			<td></td>
		</tr>
		<tr height="42">
			<td height="42" style="height:42px;width:167px;">Anti-Laminin Rabbit polyclonal antibody</td>
			<td>Sigma-Aldrich</td>
			<td>L9393</td>
			<td></td>
		</tr>
		<tr height="42">
			<td height="42" style="height:42px;width:167px;">Anti-Dystrophin Mouse Monoclonal antibody</td>
			<td>Vector Laboratories</td>
			<td>VP-D508</td>
			<td></td>
		</tr>
		<tr height="42">
			<td height="42" style="height:42px;width:167px;">Alexa Flour 594 anti-mouse IgG</td>
			<td>Life Technologies</td>
			<td>A11062</td>
			<td></td>
		</tr>
		<tr height="42">
			<td height="42" style="height:42px;width:167px;">Alexa Flour 594 anti-rabbit IgG</td>
			<td>Life Technologies</td>
			<td>A21211</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">Hematoxylin</td>
			<td>Sigma-Aldrich</td>
			<td>GHS216</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">Eosin</td>
			<td>Sigma-Aldrich</td>
			<td>HT110332</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">Xylene</td>
			<td>Acros Organics</td>
			<td>422680025</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:167px;">Cytoseal-XYL</td>
			<td style="width:205px;">Thermo</td>
			<td style="width:104px;">8312-4</td>
			<td style="width:185px;"></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:167px;">Microscope</td>
			<td style="width:205px;">Zeiss</td>
			<td style="width:104px;">Observer.Z1&#160;</td>
			<td style="width:185px;"></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:167px;">Bamboo Tablet</td>
			<td style="width:205px;">Wacom</td>
			<td style="width:104px;">CTH-661</td>
			<td style="width:185px;"></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:167px;">Prism 7.0 for Mac OS X</td>
			<td style="width:205px;">GraphPad Software, Inc.</td>
			<td style="width:104px;"></td>
			<td style="width:185px;"></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:167px;">Excel for Mac 2011</td>
			<td style="width:205px;">Microsoft Corp.</td>
			<td style="width:104px;"></td>
			<td style="width:185px;"></td>
		</tr>
		<tr height="42">
			<td height="42" style="height:42px;width:167px;">Image J</td>
			<td style="width:205px;">US National Institutes of Health</td>
			<td style="width:104px;">IJ1.46</td>
			<td style="width:185px;">http://rsbweb.nih.gov/ij/download.html</td>
		</tr>
		<tr height="22">
			<td height="22" style="height:22px;width:167px;">Microtainer</td>
			<td style="width:205px;">BD</td>
			<td style="width:104px;">365873</td>
			<td style="width:185px;"></td>
		</tr>
	</tbody>
</table>

the colon-26 carcinoma tumor-bearing mouse as a model for the study of cancer cachexia

Cancer cachexia is the progressive loss of skeletal muscle mass and adipose tissue, negative nitrogen balance, anorexia, fatigue, inflammation, and activation of lipolysis and proteolysis systems. Cancer patients with cachexia benefit less from anti-neoplastic therapies and show increased mortality1. Several animal models have been established in order to investigate the molecular causes responsible for body and muscle wasting as a result of tumor growth. Here, we describe methodologies pertaining to a well-characterized model of cancer cachexia: mice bearing the C26 carcinoma2-4. Although this model is heavily used in cachexia research, different approaches make reproducibility a potential issue. The growth of the C26 tumor causes a marked and progressive loss of body and skeletal muscle mass, accompanied by reduced muscle cross-sectional area and muscle strength3-5. Adipose tissue is also lost. Wasting is coincident with elevated circulating levels of pro-inflammatory cytokines, particularly Interleukin-6 (IL-6)3, which is directly, although not entirely, responsible for C26 cachexia. It is well-accepted that a primary mechanism by which the C26 tumor induces muscle tissue depletion is the activation of skeletal muscle proteolytic systems. Thus, expression of muscle-specific ubiquitin ligases, such as atrogin-1/MAFbx and MuRF-1, represent an accepted method for the evaluation of the ongoing muscle catabolism2. Here, we present how to execute this model in a reproducible manner and how to excise several tissues and organs (the liver, spleen, and heart), as well as fat and skeletal muscles (the gastrocnemius, tibialis anterior, and quadriceps). We also provide useful protocols that describe how to perform muscle freezing, sectioning, and fiber size quantification.

C26肿瘤生长动力学显示第一个7滞后相位 - 注射后8天，随后指数细胞生长（4 - 5 D）。肿瘤块最终到达〜体重的10％（约2克; 图 1A-B）。在第一阶段中，肿瘤可以仅触诊被定位和显示为皮肤的一小突出部。在第二阶段中，肿瘤被观察为在皮肤下质量。很少，肿瘤变得溃烂，导致一个开放的伤口;在这种情况下，鼠标从实验组中排除，并且安乐死。 </p...

Watch this Scientific Journal Video about The Colon-26 Carcinoma Tumor-bearing Mouse as a Model for the Study of Cancer Cachexia at JoVE.com

The Colon-26 Carcinoma Tumor-bearing Mouse as a Model for the Study of Cancer Cachexia

Mice bearing the Colon-26 (C26) carcinoma represent a classical model of cancer cachexia. Progressive muscle wasting occurs in association with tumor growth, over-expression of muscle-specific ubiquitin ligases, and reductions in muscle cross-sectional area. Fat loss is also observed. Cachexia is studied in a time-dependent manner with increasing severity of wasting.

结肠-26癌荷瘤小鼠为癌症恶病质的研究模型

Cancer cachexia is the progressive loss of skeletal muscle mass and adipose tissue, negative nitrogen balance, anorexia, fatigue, inflammation, and ...

the-colon-26-carcinoma-tumor-bearing-mouse-as-model-for-study-cancer

Research

JoVE Journal

Cancer Research

16.0K 次观看.  Indiana University School of Medicine. Mice bearing the Colon-26 (C26) carcinoma represent a classical model of cancer cachexia. Progressive muscle wasting occurs in association with tumor growth, over-expression of muscle-specific ubiquitin ligases, and reductions in muscle cross-sectional area. Fat loss is also observed. Cachexia is studied in a time-dependent manner with increasing severity of wasting. 

视频: The Colon-26 Carcinoma Tumor-bearing Mouse as a Model for the Study of Cancer Cachexia

Study of Viral Vectors in a Three-dimensional Liver Model Repopulated with the Human Hepatocellular Carcinoma Cell Line HepG2

This protocol describes the generation of a three-dimensional (3D) ex vivo liver model and its application to the study and development of viral vector systems. The model is obtained by repopulating the extracellular matrix of a decellularized rat liver with a human hepatocyte cell line. The model permits studies in a vascularized 3D cell system, replacing potentially harmful experiments with living animals. Another advantage is the humanized nature of the model, which is closer to human physiology than animal models.
In this study, we demonstrate the transduction of this liver model with a viral vector derived from adeno-associated viruses (AAV vector). The perfusion circuit that supplies the 3D liver model with media provides an easy means to apply the vector. The system permits monitoring of the major metabolic parameters of the liver. For final analysis, tissue samples can be taken to determine the extent of recellularization by histological techniques. Distribution of the virus vector and expression of the delivered transgene can be analyzed by quantitative PCR (qPCR), Western blotting and immunohistochemistry. Numerous applications of the vector model in basic research and in the development of gene therapeutic applications can be envisioned, including the development of novel antiviral therapeutics, cancer research, and the study of viral vectors and their potential side effects.

The recellularized extracellular matrix of a decellularized rat liver can be used as a humanized, three-dimensional ex vivo model to study the distribution and transgene expression of a virus or viral vector.

研究病毒载体在三维肝模型重新填充与人肝癌细胞株HepG2

This protocol describes the generation of a three-dimensional (3D) ex vivo liver model and its application to the study and development of viral vector ...

科研

癌症研究

A Model for Perineural Invasion in Head and Neck Squamous Cell Carcinoma

Perineural invasion (PNI) is found in approximately 40% of head and neck squamous cell carcinomas (HNSCC). Despite multimodal treatment with surgery, radiation, and chemotherapy, locoregional recurrences and distant metastases occur at higher rates, and overall survival is decreased by 40% compared to HNSCC without PNI. In vitro studies of the pathways involved in HNSCC PNI have historically been challenging given the lack of a consistent, reproducible assay. Described here is the adaptation of the dorsal root ganglion (DRG) assay for the examination of PNI in HNSCC. In this model, DRG are harvested from the spinal column of a sacrificed nude mouse and placed within a semisolid matrix. Over the subsequent days, neurites are generated and grow in a radial pattern from the cell bodies of the DRG. HNSCC cell lines are then placed peripherally around the matrix and invade preferentially along the neurites toward the DRG. This method allows for rapid evaluation of multiple treatment conditions, with very high assay success rates and reproducibility.

Perineural invasion (PNI) is a common feature of head and neck squamous cell carcinoma (HNSCC), conferring lower survival rates. Its mechanisms are poorly understood. Utilizing neurites generated from murine dorsal root ganglia confined to a semisolid matrix, the pathways involved in the PNI of HNSCC cell lines can be investigated.

在头颈部鳞状细胞癌的神经浸润模型

Perineural invasion (PNI) is found in approximately 40% of head and neck squamous cell carcinomas (HNSCC). Despite multimodal treatment with surgery, ...

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Renal cell carcinoma (RCC) affects &#62; 60,000 people in the United States annually, and ~ 30% of RCC patients have multiple metastases at the time of diagnosis. Metastatic RCC (mRCC) is incurable, with a median survival time of only 18 months. Immune-based interventions (e.g., interferon (IFN) and interleukin (IL)-2) induce durable responses in a fraction of mRCC patients, and multikinase inhibitors (e.g., sunitinib or sorafenib) or anti-VEGF receptor monoclonal antibodies (mAb) are largely palliative, as complete remissions are rare. Such shortcomings in current therapies for mRCC patients provide the rationale for the development of novel treatment protocols. A key component in the preclinical testing of new therapies for mRCC is a suitable animal model. Beneficial features that recapitulate the human condition include a primary renal tumor, renal tumor metastases, and an intact immune system to investigate any therapy-driven immune effector responses and the formation of tumor-induced immunosuppressive factors. This report describes an orthotopic mRCC mouse model that has all of these features. We describe an intrarenal implantation technique using the mouse renal adenocarcinoma cell line Renca, followed by the assessment of tumor growth in the kidney (primary site) and lungs (metastatic site).

Implementation of an orthotopic model of renal cell carcinoma in immunocompetent mice affords the investigator a clinically-relevant system defined by the presence of a primary renal tumor and lung metastases in the same animal. This system can be used to preclinically test a variety of treatments in vivo.

转移性的型号同源小鼠肾细胞癌的临床前疗法的定量和纵向评估

Renal cell carcinoma (RCC) affects &#62; 60,000 people in the United States annually, and ~ 30% of RCC patients have multiple metastases at the time of ...

Fabrication of Tongue Extracellular Matrix and Reconstitution of Tongue Squamous Cell Carcinoma In Vitro

In order to construct an effective and realistic model for tongue squamous cell carcinoma (TSCC) in vitro, the methods were created to produce decellularized tongue extracellular matrix (TEM) which provides functional scaffolds for TSCC construction. TEM provides an in vitro niche for cell growth, differentiation, and cell migration. The microstructures of native extracellular matrix (ECM) and biochemical compositions retained in the decellularized matrix provide tissue-specific niches for anchoring cells. The fabrication of TEM can be realized by deoxyribonuclease (DNase) digestion accompanied with a serious of organic or inorganic pretreatment. This protocol is easy to operate and ensures high efficiency for the decellularization. The TEM showed favorable cytocompatibility for TSCC cells under static or stirred culture conditions, which enables the construction of the TSCC model. A self-made bioreactor was also used for the persistent stirred condition for cell culture. Reconstructed TSCC using TEM showed the characteristics and properties resembling clinical TSCC histopathology, suggesting the potential in TSCC research.

Fabrication of Tongue Extracellular Matrix and Reconstitution of Tongue Squamous Cell Carcinoma In Vitro

A method is shown here for the preparation of the tongue extracellular matrix (TEM) with efficient decellularization. The TEM can be used as functional scaffolds for the reconstruction of a tongue squamous cell carcinoma (TSCC) model under static or stirred culture conditions.

舌细胞外基质的制备与舌鳞癌体外重建

In order to construct an effective and realistic model for tongue squamous cell carcinoma (TSCC) in vitro, the methods were created to produce ...

A Syngeneic Pancreatic Cancer Mouse Model to Study the Effects of Irreversible Electroporation

Pancreatic cancer (PC), a disease which kills approximately 40,000 patients each year in the US, has successfully evaded several therapeutic approaches including the promising immunotherapeutic strategies. Irreversible electroporation (IRE) is a non-thermal ablation technique that induces tumor cell death without destruction of adjacent collagenous structures, thus enabling the procedure to be performed in tumors very close to blood vessels. Unlike thermal ablation techniques, IRE results in gradual apoptotic cell death, along with immediate ablation induced necrosis, and is currently in clinical use for selected patients with locally advanced PC. An ablative, non-target specific procedure like IRE can induce a myriad of responses in the tumor microenvironment. A few studies have addressed the effects of IRE on tumor growth in other tumor types, but none have focused on PC. We have developed a syngeneic mouse model of PC in which subcutaneous (SQ) and orthotopic tumors can be successfully treated with IRE in a highly controlled setting, facilitating various longitudinal studies post procedure. This animal model serves as a robust system to study the effects of IRE and ways to improve the clinical efficacy of IRE.

Irreversible electroporation (IRE) is a non-thermal ablation technique used for the treatment of locally advanced pancreatic cancer. Being a relatively new technique, the effects of IRE on the tumor growth are poorly understood. We have developed a syngeneic mouse model that facilitates studying the effects of IRE on pancreatic cancer.

自体胰腺癌小鼠模型研究不可逆电穿孔的影响

Pancreatic cancer (PC), a disease which kills approximately 40,000 patients each year in the US, has successfully evaded several therapeutic approaches ...

Yeast As a Chassis for Developing Functional Assays to Study Human P53

The finding that the well-known mammalian P53 protein can act as a transcription factor (TF) in the yeast S. cerevisiae has allowed for the development of different functional assays to study the impacts of 1) binding site [i.e., response element (RE)] sequence variants on P53 transactivation specificity or 2) TP53 mutations, co-expressed cofactors, or small molecules on P53 transactivation activity. Different basic and translational research applications have been developed. Experimentally, these approaches exploit two major advantages of the yeast model. On one hand, the ease of genome editing enables quick construction of qualitative or quantitative reporter systems by exploiting isogenic strains that differ only at the level of a specific P53-RE to investigate sequence-specificity of P53-dependent transactivation. On the other hand, the availability of regulated systems for ectopic P53 expression allows the evaluation of transactivation in a wide range of protein expression. Reviewed in this report are extensively used systems that are based on color reporter genes, luciferase, and the growth of yeast to illustrate their main methodological steps and to critically assess their predictive power. Moreover, the extreme versatility of these approaches can be easily exploited to study different TFs including P63 and P73, which are other members of TP53 gene family.

Presented here are four protocols to construct and exploit yeast Saccharomyces cerevisiae reporter strains to study human P53 transactivation potential, impacts of its various cancer-associated mutations, co-expressed interacting proteins, and the effects of specific small molecules.

酵母作为开发功能分析研究人类P53的机箱

The finding that the well-known mammalian P53 protein can act as a transcription factor (TF) in the yeast S. cerevisiae has allowed for the development of ...

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

The contribution of neutrophils to the regulation of tumorigenesis is getting increased attention. These cells are heterogeneous, and depending on the tumor milieu can possess pro- or anti-tumor capacity. One of the important cytokines regulating neutrophil functions in a tumor context are type I interferons. In the presence of interferons, neutrophils gain anti-tumor properties, including cytotoxicity or stimulation of the immune system. Conversely, the absence of an interferon signaling results in prominent pro-tumor activity, characterized with strong stimulation of tumor angiogenesis. Recently, we could demonstrate that pro-angiogenic properties of neutrophils depend on the activation of nicotinamide phosphoribosyltransferase (NAMPT) signaling pathway in these cells. Inhibition of this pathway in tumor-associated neutrophils leads to their potent anti-angiogenic phenotype. Here, we demonstrate our newly established model allowing in vivo evaluation of tumorigenic potential of manipulated tumor-associated neutrophils (TANs). Shortly, pro-angiogenic tumor-associated neutrophils can be isolated from tumor-bearing interferon-deficient mice and repolarized into anti-angiogenic phenotype by blocking of NAMPT signaling. The angiogenic activity of these cells can be subsequently evaluated using an aortic ring assay. Anti-angiogenic TANs can be transferred into tumor-bearing wild type recipients and tumor growth should be monitored for 14 days. At day 14 mice are sacrificed, tumors removed and cut with their vascularization assessed. Overall, our protocol provides a novel tool to in vivo evaluate angiogenic capacity of primary cells, such as tumor-associated neutrophils, without a need to use artificial neutrophil cell line models. vc

Here, we show therapeutic potential of anti-angiogenic tumor-associated neutrophils after their transfer into tumor-bearing mice. This protocol can be used to manipulate neutrophil activity ex vivo and to subsequently evaluate their functionality in vivo&#160;in developing tumors. It is an appropriate model for studying potential neutrophil-based immunotherapies.

将操纵的肿瘤相关中性粒细胞转移到肿瘤携带小鼠中,以研究其血管生成潜力在Vivo

The contribution of neutrophils to the regulation of tumorigenesis is getting increased attention. These cells are heterogeneous, and depending on the ...

Isolation of Primary Cancer-Associated Fibroblasts from a Syngeneic Murine Model of Breast Cancer for the Study of Targeted Nanoparticles

Cancer-associated fibroblasts (CAFs) are key actors in the context of the tumor microenvironment. Despite being reduced in number as compared to tumor cells, CAFs regulate tumor progression and provide protection from antitumor immunity. Emerging anticancer strategies aim to remodel the tumor microenvironment through the ablation of pro-tumorigenic CAFs or reprogramming of CAFs functions and their activation status. A promising approach is the development of nanosized delivery agents able to target CAFs, thus allowing the specific delivery of drugs and active molecules. In this context, a cellular model of CAFs may provide a useful tool for in vitro screening and preliminary investigation of such nanoformulations.
This study describes the isolation and culture of primary CAFs from the syngeneic 4T1 murine model of triple-negative breast cancer. Magnetic beads were used in a 2-step separation process to extract CAFs from dissociated tumors. Immunophenotyping control was performed using flow cytometry after each passage to verify the process yield. Isolated CAFs can be employed to study the targeting capability of different nanoformulations designed to tackle the tumor microenvironment. Fluorescently labeled H-ferritin nanocages were used as candidate nanoparticles to set up the method. Nanoparticles, either bare or conjugated with a targeting ligand, were analyzed for their binding to CAFs. The results suggest that ex vivo extraction of breast CAFs may be a useful system to test and validate nanoparticles for the specific targeting of tumorigenic CAFs.

This paper aims to provide a protocol for the isolation and culture of primary cancer-associated fibroblasts from a syngeneic murine model of triple-negative breast cancer and their application for the preclinical study of novel nanoparticles designed to target the tumor microenvironment.&#160;

将原发性癌症相关纤维细胞与乳腺癌的合成素 Murine 模型分离，用于靶向纳米粒子的研究

Cancer-associated fibroblasts (CAFs) are key actors in the context of the tumor microenvironment. Despite being reduced in number as compared to tumor ...

Portal Vein Injection of Colorectal Cancer Organoids to Study the Liver Metastasis Stroma

Hepatic metastasis of colorectal cancer (CRC) is a leading cause of cancer-related death. Cancer-associated fibroblasts (CAFs), a major component of the tumor microenvironment, play a crucial role in metastatic CRC progression and predict poor patient prognosis. However, there is a lack of satisfactory mouse models to study the crosstalk between metastatic cancer cells and CAFs. Here, we present a method to investigate how liver metastasis progression is regulated by the metastatic niche and possibly could be restrained by stroma-directed therapy. Portal vein injection of CRC organoids generated a desmoplastic reaction, which faithfully recapitulated the fibroblast-rich histology of human CRC liver metastases. This model was tissue-specific with a higher tumor burden in the liver when compared to an intra-splenic injection model, simplifying mouse survival analyses. By injecting luciferase-expressing tumor organoids, tumor growth kinetics could be monitored by in vivo imaging. Moreover, this preclinical model provides a useful platform to assess the efficacy of therapeutics targeting the tumor mesenchyme. We describe methods to examine whether adeno-associated virus-mediated delivery of a tumor-inhibiting stromal gene to hepatocytes could remodel the tumor microenvironment and improve mouse survival. This approach enables the development and assessment of novel therapeutic strategies to inhibit hepatic metastasis of CRC.

Portal vein injection of colorectal cancer (CRC) organoids generates stroma-rich liver metastasis. This mouse model of CRC hepatic metastasis represents a useful tool to study tumor-stroma interactions and develop novel stroma-directed therapeutics such as adeno-associated virus-mediated gene therapies.

门静脉注射结直肠癌类器官研究肝转移基质

Hepatic metastasis of colorectal cancer (CRC) is a leading cause of cancer-related death. Cancer-associated fibroblasts (CAFs), a major component of the ...

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

The aggressiveness and lack of well-tolerated and widely effective treatments for advanced hepatocellular carcinoma (HCC), the predominant form of liver cancer, rationalize its rank as the second most common cause of cancer-related death. Preclinical models need to be adapted to recapitulate the human conditions to select the best therapeutic candidates for clinical development and aid the delivery of personalized medicine. Three-dimensional (3D) cellular spheroid models show promise as an emerging in vitro alternative to two-dimensional (2D) monolayer cultures. Here, we describe a 3D tumor spheroid&#160;model which exploits the ability of individual cells to aggregate when maintained in hanging droplets, and is more representative of an in vivo environment than standard monolayers. Furthermore, 3D spheroids can be produced by combining homotypic or heterotypic cells, more reflective of the cellular heterogeneity in vivo, potentially enabling the study of environmental interactions that can influence progression and treatment responses. The current research optimized the cell density to form 3D homotypic and heterotypic tumor spheroids by immobilizing cell suspensions on the lids of standard 10 cm3 Petri dishes. Longitudinal analysis was performed to generate growth curves for homotypic versus heterotypic tumor/fibroblasts spheroids. Finally, the proliferative impact of fibroblasts (COS7 cells) and liver myofibroblasts (LX2) on homotypic tumor (Hep3B) spheroids was investigated. A seeding density of 3,000 cells (in 20 &#181;L media) successfully yielded Huh7/COS7 heterotypic spheroids, which displayed a steady increase in size up to culture day 8, followed by growth retardation. This finding was corroborated using Hep3B homotypic spheroids cultured in LX2 (human hepatic stellate cell line) conditioned medium (CM). LX2 CM triggered the proliferation of Hep3B spheroids compared to control tumor spheroids. In conclusion, this protocol has shown that 3D tumor spheroids can be used as a simple, economical, and prescreen in vitro tool to study tumor-stromal interactions more comprehensively.

Comprehensive in vitro models that faithfully recapitulate the relevant human disease are lacking. The current study presents three-dimensional (3D) tumor spheroid creation and culture, a reliable in vitro tool to study the tumor-stromal interaction in human hepatocellular carcinoma.

一种三维球体模型研究肝细胞癌肿瘤-基质相互作用

The aggressiveness and lack of well-tolerated and widely effective treatments for advanced hepatocellular carcinoma (HCC), the predominant form of liver ...